Specifically, retatrutide acts on three receptors: GLP-1, GIP, and glucagon
In summary, the growing body of evidence positions GLP-1 receptor agonists as essential medications at the intersection of endocrinology and cardiovascular medicine
(2011) mapped this mechanism in detail directly on isolated tenocytes in a laboratory dish
New Hampshire and South Carolina are also ending Medicaid coverage of GLP-1s for weight loss at the start of next year, and Rhode Island is considering discontinuing coverage, citing similar budgetary concerns
Wegovy and Zepbound are approved for chronic weight management
The biomarker changes (lower blood pressure, better lipid profile) are favourable and create a reasonable prior expectation, but the dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes) is not expected to report until late 2027 or early 2028